Duality Biotherapeutics, Inc. (HKG:9606)

Market Cap	16.20B -8.9%
Revenue (ttm)	2.06B -4.6%
Net Income	-2.89B
EPS	-44.32
Shares Out	90.43M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,262,279
Open	178.90
Previous Close	179.10
Day's Range	177.10 - 191.60
52-Week Range	162.30 - 563.50
Beta	n/a
Analysts	Strong Buy
Price Target	436.10 (+135.6%)
Earnings Date	Mar 23, 2026

About Duality Biotherapeutics

Duality Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-drug conjugate (ADC) therapeutics to treat cancer, autoimmune diseases, and others. The company provides DB-1303/BNT323, a HER2 ADC candidate targeting cancers, including endometrial cancer1 and breast cancer2; DB-1311/BNT324, a B7-H3 ADC candidate targeting cancers, such as small-cell lung cancer3, castration-resistant prostate cancer4, esophageal squamous cell carcinoma5, and head and neck squamous cell carcinoma; and other clinical-stag...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Employees: 231
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 9606

Financial Performance

In 2025, Duality Biotherapeutics's revenue was 1.85 billion, a decrease of -4.61% compared to the previous year's 1.94 billion. Losses were -2.59 billion, 147.0% more than in 2024.

Financial numbers in CNY

Analyst Summary

According to 8 analysts, the average rating for 9606 stock is "Strong Buy." The 12-month stock price target is $436.10, which is an increase of 135.60% from the latest price.

Price Target

$436.10

(135.60% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jun 18, 2026

Data Sources Report a data error